Investor · 1 deal
Melbourne, VIC
Every published round St. Vincent's Hospital took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| EpiMinder | Series A | Oct 2021 | $18m | Participant | @AuManufacturing (Wed 16 Mar 2022), @AuManufacturing (Tue 6 Oct 2020) |
Companies St. Vincent's Hospital has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| EpiMinder | Oct 2021, Series A | 1 | 0 |
Fund closes reported for St. Vincent's Hospital, as distinct from the investments it has made.
Companies St. Vincent's Hospital has backed that another company then bought. An exit for the holding, not a deal St. Vincent's Hospital did.
| Name | Role | Sources |
|---|---|---|
| Professor Mark Cook | Neurologist | Startup Daily |
| Dr Chris Hayward | Heart Failure Cardiologist | GBS Ventures |
Stories naming St. Vincent's Hospital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of Melbourne-based biotech Neurala Biosciences, founded by two researchers turning DMT and harmala compounds into medicines, covering its origins, grant and investor backing totalling $4.5m, and planned first-in-human studies.
Profile of scientist-entrepreneur Andrew Wilks tracing his path from cancer research to founding drug developer Cytopia and launching SYNthesis BioVentures, a therapeutics fund that recently secured $30 million from wealthy individuals and family offices.
Epi-Minder has completed a $16 million bridge round with its existing shareholders to fund expanded clinical trials, product development and manufacturing of its long-term epilepsy monitoring device.
Three Victorian startups completed the first CivVic Labs accelerator cohort, each receiving a $150,000 grant from the Better Care Victoria Innovation Fund and contracts to build prototypes with health and transport agencies.
Sunshine Heart's chief executive reports to shareholders on the C-Pulse trial: halfway through its US feasibility study, first two minimally invasive implants completed and new hospitals in Australia, Canada and the US joining.